>Q1 y-o-y cc growth of -3.3% in line with expectations. Decent bookings - Q1 2024 sales came to € 5,527m down -3.3% at cc. This figure is just in line with expectations in reported terms and +20bp above at cc (vs ODDO BHF: € 5,518m, down -3.6% y-o-y cc; Css: € 5,527m down -3.5% y-o-y cc). Organic growth came to -3.6%, +20bp above Css expectations (vs ODDO BHF: -4.0% y-o-y org and Css at -3.8% y-o-y org), a slowdown vs Q4 2023 (-0.9%). This implies q-o-q org. growth of...
Emittent / Herausgeber: HRK LUNIS AG / Schlagwort(e): Fusionen & Übernahmen/Firmenübernahme HRK LUNIS AG übernimmt ProVidens Vermögensmanagement GmbH in Hamburg und baut führende Position als bankenunabhängiger Vermögensverwalter aus 30.04.2024 / 10:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Artur J. Montanhas, Andreas Brandt, HRK LUNIS AG (Euro-Magazin_Bildquelle_Julian Mezger_Finanzen Verlag) René Stadtmüller, ProVidens (Bildquelle: Martina van Kann) Stefan Mönkediek, ProVidens (Bildquelle: Martina van Kann) Pressemi...
EQS-News: NanoRepro AG / Schlagwort(e): Personalie NanoRepro AG: Aufsichtsrat bestätigt CEO Lisa Jüngst 30.04.2024 / 10:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. NanoRepro AG: Aufsichtsrat bestätigt CEO Lisa Jüngst Marburg, 30. April 2024 – Der Aufsichtsrat der NanoRepro AG (ISIN: DE0006577109/ Symbol: NN6) hat das Mandat von Vorstandsmitglied Lisa Jüngst einstimmig um drei Jahre verlängert und schafft damit die Voraussetzung für eine konstante und stabile Führung der Gesellschaft auf dem Weg zu einem international agierende...
A director at MCI Capital S.A. sold 961,528 shares at 30.000PLN and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
>2023 results in line with our expectations - Yesterday evening, Waga Energy published its FY 2023 results. As a reminder, 2023 sales were € 33.3m, i.e. a 74% increase vs 2022 (2022 sales at € 19.2m). EBITDA was down by € 1.6m to -€ 4.8m (vs -€ 3.2m in 2022) in line with our forecasts. H2 2023 EBITDA was -€ 1.7m, up sharply vs H1 2023 (-€ 3.1m). EBIT fell to -€ 14.5m (vs -€ 8.2m in 2022), a shade below our forecast. Lastly, the group reported a net loss of -€ 16m (...
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva PharmaceuticalsThe high-concentration interchangeable biosimilar to Humira® manufactured by Alvotech will be distributed under Quallent’s private-label REYKJAVIK, ICELAND, PARSIPPANY, N.J., and TEL A...
Alvotech semur við Quallent Pharmaceuticals um markaðssetningu á hliðstæðu við Humira í Bandaríkjunum Alvotech mun framleiða líftæknilyfjahliðstæðu sína í háum styrk með útskiptileika við Humira (adalimumab) fyrir Quallent Pharmaceuticals, dótturfélag Cigna Alvotech (NASDAQ: ALVO) tilkynnti í dag að nýgerður samningur í Bandaríkjunum um dreifingu og sölu á líftæknilyfjahliðstæðu Alvotech í háum styrk með útskiptileika við Humira (adalimumab) sé við Quallent Pharmaceuticals, dótturfélag Cigna. Samningurinn er gerður með samþykki Teva Pharmaceuticals, sem er samstarfsaðili Alvotech í Ban...
New number of votes and shares outstanding Where the company increases or reduces the total number of shares or votes in the company, the company shall by law publish information regarding the change. At the 2011 Annual General Meeting, a share conversion clause was added to Industrivärden’s articles of association. Shareholders have the right at any time to request conversion of Class A shares to Class C shares. During the month of April 2024, 3,104,052 Class A shares were converted to 3,104,052 Class C shares. Following the share conversion, the number of votes in the company ...
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva PharmaceuticalsThe high-concentration interchangeable biosimilar to Humira® manufactured by Alvotech will be distributed under Quallent’s private-label REYKJAVIK, Iceland and PARSIPPANY, N.J. and TEL AV...
Nokia and Vodafone complete successful Open RAN trial in Italy Press ReleaseNokia and Vodafone complete successful Open RAN trial in Italy Nokia and Vodafone are working together to boost the deployment of Open RAN solutions for a flexible network evolution.Companies reached milestone with successful Open RAN call on Vodafone Italy’s live network. 30 April 2024Espoo, Finland – Nokia and Vodafone today announced that they have successfully completed an end-to-end Open RAN trial on Vodafone Italy’s live 5G standalone network. The trial utilized Nokia’s AirScale Massive MIMO radios and Nok...
Nytt antal röster och utestående aktier Bolaget har en skyldighet enligt lag att offentliggöra uppgifter om en förändring i totala antalet aktier eller röster i bolaget. Vid årsstämman 2011 infördes ett omvandlingsförbehåll i Industrivärdens bolagsordning. Aktieägare har rätt att när som helst begära omvandling av A-aktier till C-aktier. Under april månad 2024 har omvandlingar skett av 3 104 052 A-aktier till 3 104 052 C-aktier. Efter omvandlingen uppgår antalet röster i bolaget till 263 396 693,5. Det totala antalet registrerade aktier i bolaget uppgår till 431 899 108, varav 24...
Share Buyback Transaction Details April 25 – April 29, 2024 Share Buyback Transaction Details April 25 – April 29, 2024 April 30, 2024 - Wolters Kluwer (Euronext: WKL), a global leading provider of expert solutions, insights and services for professionals, today reports that it has repurchased 100,546 of its own ordinary shares in the period from April 25, 2024, up to and including April 29, 2024, for 14.1 million and at an average share price of €140.32. The previously disclosed third-party agreement to repurchase shares for €205 million during the period starting February 23, 20...
A director at Fitness Prime sold 1,400,000 shares at 0.000EGP and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
A director at Wuxi Lead Intelligent Equipment Co Ltd bought 2,335,400 shares at 21.410CNY and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
A director at Azerion Group N.V. bought 3,571,428 shares at 1.400EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
MOODY'S INVESTORS SERVICE 1Moody’s Ratings, GS칼텍스의 ‘Baa1’ 신용등급 재확인; 전망 ‘안정적’ 2024 년 4 월 30 일、 홍콩 、 한국어 보도자료는 영문 보도자료의 번역본입니다. 한국어와 영문 보도자료 간에 상이한 점이 있을 경우 영어 원문이 우선합니다.Moody’s Ratings(이하 ‘무디스’)는 GS칼텍스의 ‘Baa1’ 선순위 무담보 채권등급을 재확인하고 ‘안정적’ 전망을 유지하였다.“GS칼텍스의 신용등급을 재확인하고 ‘안정적’ 전망을 유지한 것은 동사가 지속적인 차입금 축소를 토...
1Q'24 vs. 1Q'23: NII: € 11.983 Bn (+17.7% vs. +11.5% BS(e) and +12.6% consensus); Total Revenues: € 15.380 Bn (+10.4% vs. +8.4% BS(e) and +8.5% consensus); Operating Income: € 8.833 Bn (+13.4% vs. +10.5% BS(e) and +10.8% consensus); Net Profit: € 2.852 Bn (+10.9% vs. +12.2% BS(e) and 12.3% consensus). 1Q'24 vs. 4Q'23: NII: € 11.983 Bn (+7.7% vs. +2.1% BS(e) and +3.1% consensus); Total Revenues: € 15.380 Bn (+5.7% vs. +3.8% BS(e) and +3.9% consensus); Operating Income: € 8.833 Bn (+9.2% vs. +6.4...
Poland has seen the earliest recovery in consumer spending in the European Union, as real retail sales growth flipped to positive territory in October 2023, after contracting since February 2023. The expectation for this year is that retail spending volume growth will accelerate gradually and, according to our model projection, the peak will be reached this summer, with an expansion of 10% yoy, up from 6% yoy currently. The two key ingredients of the recovery are an improvement in consumer confi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.